miRNA Expression Profiling in G1 and G2 Pancreatic Neuroendocrine Tumors

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Pancreatic neuroendocrine neoplasms (PanNETs) present increasing clinical challenges with rising incidence and varied prognoses.
• Accurate grading of PanNETs is crucial for determining patient prognosis and guiding treatment strategies.
• Identifying reliable biomarkers for PanNET grading remains an active area of research.

Purpose of the Study:

• To investigate specific microRNAs (miRNAs) as potential diagnostic biomarkers for differentiating between Grade 1 (G1) and Grade 2 (G2) pancreatic neuroendocrine tumors (PanNETs).
• To evaluate the diagnostic performance of miRNA combinations in classifying PanNET grades.

Main Methods:

• Analysis of 33 formalin-fixed, paraffin-embedded PanNET samples (17 G1, 16 G2).
• Validation of literature-based miRNAs using real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR).
• Next-generation sequencing to identify differentially expressed miRNAs between G1 and G2 tumors, followed by RT-qPCR validation and machine learning analysis.

Main Results:

• Significant downregulation of *miR-130b-3p* and *miR-106b* was observed in G2 PanNETs compared to G1.
• *miR-30d-5p* was also confirmed to be downregulated in G2 tumors.
• A combination of five miRNAs (*miR-106b + miR-130b-3p + miR-127-3p + miR-129-5p + miR-30d-5p*) achieved the highest diagnostic performance using a machine learning algorithm, with a sensitivity of 83.33% and specificity of 87.5% in distinguishing G1 from G2 PanNETs.

Conclusions:

• MicroRNAs hold significant potential as biomarkers for stratifying PanNET grades.
• The identified miRNA combination demonstrates promising diagnostic accuracy for differentiating between G1 and G2 PanNETs.
• Further research is warranted to validate these findings and improve their clinical utility for patient management.